CA3086325A1 - Methodes et compositions permettant d'induire une reponse immunitaire contre le virus de l'hepatite b (vhb) - Google Patents
Methodes et compositions permettant d'induire une reponse immunitaire contre le virus de l'hepatite b (vhb) Download PDFInfo
- Publication number
- CA3086325A1 CA3086325A1 CA3086325A CA3086325A CA3086325A1 CA 3086325 A1 CA3086325 A1 CA 3086325A1 CA 3086325 A CA3086325 A CA 3086325A CA 3086325 A CA3086325 A CA 3086325A CA 3086325 A1 CA3086325 A1 CA 3086325A1
- Authority
- CA
- Canada
- Prior art keywords
- hbv
- seq
- antigen
- sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des vecteurs du virus modifié de la vaccine Ankara (MVA) et des vecteurs d'adénovirus codant pour des antigènes du VHB. L'invention concerne également des méthodes d'amélioration d'une réponse immunitaire chez un sujet humain en utilisant les vecteurs de MVA et d'adénovirus codant pour des antigènes du VHB dans un régime d'amorçage/d'amplification pour améliorer la réponse immunitaire chez le sujet humain.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762607439P | 2017-12-19 | 2017-12-19 | |
US62/607,439 | 2017-12-19 | ||
IB2017058148 | 2017-12-19 | ||
IBPCT/IB2017/058148 | 2017-12-19 | ||
PCT/IB2018/060257 WO2019123250A1 (fr) | 2017-12-19 | 2018-12-18 | Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb) |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3086325A1 true CA3086325A1 (fr) | 2019-06-27 |
Family
ID=65201641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3086325A Pending CA3086325A1 (fr) | 2017-12-19 | 2018-12-18 | Methodes et compositions permettant d'induire une reponse immunitaire contre le virus de l'hepatite b (vhb) |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3727446A1 (fr) |
JP (1) | JP2021506300A (fr) |
KR (1) | KR20200100745A (fr) |
CN (1) | CN111741766A (fr) |
AU (1) | AU2018389786A1 (fr) |
BR (1) | BR112020012273A2 (fr) |
CA (1) | CA3086325A1 (fr) |
IL (1) | IL275423A (fr) |
MA (1) | MA51312A (fr) |
MX (1) | MX2020006471A (fr) |
SG (1) | SG11202005710YA (fr) |
WO (1) | WO2019123250A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
WO2020255055A1 (fr) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA92121A (fr) | 1904-11-07 | 1905-03-14 | William Waid Paddock | Filtre a pression |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
WO1998010087A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Vecteurs d'adenovirus de chimpanze |
JP2001520537A (ja) | 1997-04-03 | 2001-10-30 | エレクトロフェクト・アクティーゼルスカブ | 医薬品と核酸の骨格筋への導入方法 |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
KR20010020571A (ko) | 1997-06-30 | 2001-03-15 | 자끄 사비나 | 횡문근중으로 개선된 핵산 전달방법 및 이를 위한콤비네이션 |
JP2003505114A (ja) | 1998-07-13 | 2003-02-12 | ジェネトロニクス、インコーポレーテッド | パルス電場による皮膚および筋肉を標的とした遺伝子治療 |
US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
DE60043126D1 (de) | 1999-05-17 | 2009-11-19 | Crucell Holland Bv | Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
EP1598425A1 (fr) | 2000-11-23 | 2005-11-23 | Bavarian Nordic A/S | Variant modifié du virus de la vaccine ankara |
CN101397574A (zh) | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US7285265B2 (en) | 2002-04-25 | 2007-10-23 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
AU2005221687A1 (en) | 2004-03-08 | 2005-09-22 | Ichor Medical Systems, Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
CN101248173A (zh) * | 2005-04-08 | 2008-08-20 | 墨尔本保健公司 | 对于抗病毒核苷试剂具有抗性的乙型肝炎病毒变异体及其应用 |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
CA2666501C (fr) | 2006-10-17 | 2017-03-21 | Vgx Pharmaceuticals, Inc. | Dispositifs d'electroporation et leurs procedes d'utilisation pour l'electroporation de cellules de mammiferes |
WO2009056535A2 (fr) * | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Procédés et kits permettant d'induire une réponse de ltc en utilisant un schéma de primovaccination/rappel |
NZ592082A (en) | 2008-11-27 | 2013-03-28 | Bavarian Nordic As | Promoters for recombinant viral expression |
WO2010085984A1 (fr) | 2009-02-02 | 2010-08-05 | Okairos Ag | Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations |
AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
CA2770075C (fr) * | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition pour le traitement d'une infection par le virus de l'hepatite b |
AU2011343798B2 (en) | 2010-12-14 | 2016-07-14 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
SG10201704657WA (en) | 2012-10-28 | 2017-07-28 | Bavarian Nordic As | Pr13.5 promoter for robust t-cell and antibody responses |
KR102565284B1 (ko) | 2015-07-31 | 2023-08-08 | 버베리안 노딕 에이/에스 | 폭스바이러스에서 발현을 증강하기 위한 프로모터 |
DK3402888T3 (da) * | 2016-01-12 | 2020-11-30 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Middel og fremgangsmåder til behandling af hbv |
KR102535764B1 (ko) | 2016-03-28 | 2023-05-30 | 아이커 메디칼 시스템스 인코포레이티드 | 치료제를 전달하기 위한 장치 |
-
2018
- 2018-12-18 MX MX2020006471A patent/MX2020006471A/es unknown
- 2018-12-18 MA MA051312A patent/MA51312A/fr unknown
- 2018-12-18 EP EP18839618.8A patent/EP3727446A1/fr not_active Withdrawn
- 2018-12-18 CA CA3086325A patent/CA3086325A1/fr active Pending
- 2018-12-18 JP JP2020533786A patent/JP2021506300A/ja not_active Withdrawn
- 2018-12-18 KR KR1020207020749A patent/KR20200100745A/ko unknown
- 2018-12-18 WO PCT/IB2018/060257 patent/WO2019123250A1/fr unknown
- 2018-12-18 SG SG11202005710YA patent/SG11202005710YA/en unknown
- 2018-12-18 CN CN201880089584.0A patent/CN111741766A/zh active Pending
- 2018-12-18 AU AU2018389786A patent/AU2018389786A1/en not_active Abandoned
- 2018-12-18 BR BR112020012273-4A patent/BR112020012273A2/pt not_active IP Right Cessation
-
2020
- 2020-06-16 IL IL275423A patent/IL275423A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019123250A1 (fr) | 2019-06-27 |
IL275423A (en) | 2020-08-31 |
SG11202005710YA (en) | 2020-07-29 |
BR112020012273A2 (pt) | 2020-11-24 |
MX2020006471A (es) | 2020-09-22 |
AU2018389786A1 (en) | 2020-06-18 |
CN111741766A (zh) | 2020-10-02 |
EP3727446A1 (fr) | 2020-10-28 |
MA51312A (fr) | 2020-10-28 |
JP2021506300A (ja) | 2021-02-22 |
KR20200100745A (ko) | 2020-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11020476B2 (en) | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) | |
US11725194B2 (en) | Hepatitis B virus (HBV) vaccines and uses thereof | |
US10912827B2 (en) | Means and methods for treating HBV | |
EP3727445B1 (fr) | Vaccin contre le virus de l'hepatite b et utilisation | |
CA3086325A1 (fr) | Methodes et compositions permettant d'induire une reponse immunitaire contre le virus de l'hepatite b (vhb) | |
US20220305116A1 (en) | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives | |
WO2020255013A1 (fr) | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de modulateurs d'assemblage de capside qui sont des dérivés d'amide | |
US20220233526A1 (en) | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators | |
US20220226467A1 (en) | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof | |
US20220249647A1 (en) | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators | |
WO2020255010A1 (fr) | Combinaison d'une construction d'interleukine 12 recombinante et de vaccins contre le virus de l'hépatite b (vhb) | |
WO2020255021A1 (fr) | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'inhibiteur de pdl1 ou pd1 à petite molécule | |
WO2020254876A1 (fr) | Administration de particules de type viral de vaccins contre le virus de l'hépatite b (vhb) | |
US20220324916A1 (en) | Hepatitis B Virus (HBV) Vaccines and Uses Thereof | |
TW201928061A (zh) | 誘發抗b型肝炎病毒(hbv)免疫反應之方法及組合物 | |
OA19833A (en) | Hepatitis B virus (HBV) vaccines and uses thereof. | |
EA045279B1 (ru) | Вакцины против вируса гепатита b (hbv) и их применение | |
TW201930594A (zh) | B型肝炎病毒(hbv)疫苗及其用途 |